Hemant Surgical Industries Limited has announced the acquisition of a 66.66 percent controlling stake in Lifesenz Cancer Research Labs Private Limited for ₹19.98 crore, marking a significant step in the company’s strategy to expand into advanced healthcare and precision oncology solutions. Effective June 1, 2026, Lifesenz has become a subsidiary of Hemant Surgical, providing the company with a strategic entry into one of the fastest-growing segments of the global healthcare industry. The acquisition aligns with Hemant Surgical’s objective of strengthening its healthcare portfolio through innovative and specialized medical solutions that address evolving patient and clinical needs.
The global oncology market continues to experience rapid growth, driven by rising cancer incidence rates, advancements in personalized medicine and increasing demand for targeted treatment approaches. Lifesenz operates in the field of precision oncology, supporting clinicians with patient-specific treatment selection through advanced ex-vivo chemosensitivity testing using patient-derived three-dimensional cancer cell models. This technology enables oncologists to assess the potential effectiveness of various treatment options before therapy begins, allowing for more informed treatment planning and improved clinical decision-making.
Hemant Surgical believes the integration of Lifesenz’s scientific capabilities with its own established healthcare network will create significant opportunities for growth. The company expects the acquisition to enhance its presence in specialized healthcare markets, deepen engagement with hospitals and healthcare institutions, expand its portfolio of differentiated medical solutions and strengthen its position in innovation-driven healthcare segments.
In addition to broadening its product and service offerings, the transaction creates a foundation for future participation in precision medicine and advanced cancer care initiatives. Lifesenz has already developed collaborations with oncologists, hospitals, research organizations and healthcare stakeholders, providing a platform for further expansion and increased adoption of precision oncology solutions across India.
Management acknowledged that Lifesenz remains in a development and growth phase, with ongoing investments in research, infrastructure, technology and market expansion. While immediate financial contributions may be limited, the acquisition has been evaluated from a long-term strategic perspective focused on future growth opportunities and value creation.
Commenting on the acquisition, Hanskumar Shamji Shah, Managing Director of Hemant Surgical Industries Limited, said precision oncology represents an important and rapidly evolving area of healthcare. He noted that combining Lifesenz’s scientific expertise with Hemant Surgical’s healthcare ecosystem creates a strong platform for innovation, improved patient outcomes and sustainable business growth.
Founded in 1985, Hemant Surgical Industries Limited is a BSE-listed healthcare company engaged in the import, manufacturing and marketing of surgical, pharmaceutical and healthcare products. The company continues to pursue strategic initiatives aimed at expanding its healthcare footprint while delivering long-term value to stakeholders.
